EPIDERMAL
MOLECULAR TARGETEpidermal growth factor receptor (human)
EPIDERMAL (Epidermal growth factor receptor (human)) is targeted by 18 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting EPIDERMAL
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Afatinib | 5.18 | 176 |
| 2 | Sorafenib | 2.83 | 16 |
| 3 | tyrphostin ag 1478 | 2.40 | 10 |
| 4 | ag490 | 2.30 | 9 |
| 5 | plumbagin [Supplementary Concept] | 1.39 | 3 |
| 6 | Crizotinib | 1.39 | 3 |
| 7 | daph | 1.39 | 3 |
| 8 | Axitinib | 1.10 | 2 |
| 9 | Dasatinib | 1.10 | 2 |
| 10 | Quercetin | 0.69 | 1 |
| 11 | alyssin [Supplementary Concept] | 0.69 | 1 |
| 12 | Astemizole Antihistamine drug now withdrawn from | 0.69 | 1 |
| 13 | Bacitracin | 0.69 | 1 |
| 14 | butein | 0.69 | 1 |
| 15 | Hexachlorophene | 0.69 | 1 |
| 16 | Levodopa | 0.69 | 1 |
| 17 | Methyldopa | 0.69 | 1 |
| 18 | Vemurafenib | 0.69 | 1 |
About EPIDERMAL as a Drug Target
EPIDERMAL (Epidermal growth factor receptor (human)) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 18 compounds with documented EPIDERMAL interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
EPIDERMAL inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.